Status:
COMPLETED
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
Lead Sponsor:
Asan Medical Center
Conditions:
Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Lymphoma, Multiple Myeloma
Eligibility:
All Genders
16-75 years
Brief Summary
The purpose of this study was to explore the regulatory and effector T cell-related immune mechanisms associated with the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic...
Eligibility Criteria
Inclusion
- \- 1. Patients: Patients aged 16 to 75 years receiving allogeneic hematopoietic stem cell transplantation for hematologic malignancies at Seoul Asan Medical Center.
- 2\. Family members: Family members of patients under 75 years of age who meet Criterion 1 and are willing to donate peripheral blood hematopoietic stem cells.
Exclusion
- Patients receiving cord blood transplantation.
Key Trial Info
Start Date :
May 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 20 2025
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT07150468
Start Date
May 13 2021
End Date
August 20 2025
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea